MinorBiguanides. Oral antihyperglycemic agents×Alpha-adrenergic blockers for prostatic disorders
Updated · Methodology
Mechanism
Metformin is not metabolised in the body and is excreted unchanged by the kidneys through glomerular filtration and tubular secretion. It is a substrate of the organic cation transporters OCT1 and OCT2, and OCT2 inhibitors can slow its elimination (metformin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Tamsulosin is slowly metabolised in the liver by CYP3A4 and CYP2D6, and about 9% of the dose is excreted unchanged in the urine (tamsulosin SmPC, AEMPS). Drugs that can acutely impair renal function, such as antihypertensives, are started with caution in people taking metformin (metformin SmPC, AEMPS). Tamsulosin is intended only for prostate disease, and in studies it caused no clinically significant fall in blood pressure (tamsulosin SmPC, AEMPS). Tamsulosin is not on the lists of drugs that change the elimination or effect of metformin, and metformin is not among the tamsulosin interactions (metformin and tamsulosin SmPCs, AEMPS; metformin and tamsulosin labels, US Food and Drug Administration, FDA).
Symptoms
The documents describe no symptoms linked to this combination. In individual cases, tamsulosin lowers blood pressure, rarely enough to cause fainting. The first signs of orthostatic hypotension are dizziness and weakness (tamsulosin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). At the start of treatment metformin very commonly causes nausea, vomiting, diarrhoea, abdominal pain and loss of appetite. Its very rare but serious complication is lactic acidosis, with acidotic breathlessness, abdominal pain, muscle cramps, weakness and hypothermia, followed by coma (metformin SmPC, AEMPS).
Management
According to the documents, the combination is acceptable, and the doses of metformin and tamsulosin need no change. No document names the pair, and their elimination pathways do not overlap (metformin and tamsulosin SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS; metformin and tamsulosin labels, US Food and Drug Administration, FDA). Glomerular filtration rate (GFR) is assessed before metformin starts and at least once a year after that. In older people and in those at risk of worsening renal function, it is assessed every 3–6 months. Metformin is contraindicated when GFR is below 30 mL/min (metformin SmPC, AEMPS). In severe renal impairment with creatinine clearance below 10 mL/min, tamsulosin is used with caution, because such patients have not been studied (tamsulosin SmPC, AEMPS). At the first signs of orthostatic hypotension, such as dizziness or weakness, the person is advised to sit or lie down until the symptoms pass (tamsulosin SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica Dianben 850 mg comprimidos recubiertos con película (metformina) (2025)– AEMPS, CIMA, nº registro 55211, revisión 03/2025, secciones 4.4 y 4.5
- AEMPS: Ficha técnica: Tamsulosina (Omnic 0,4 mg) (nº registro 61426), secciones 4.2, 4.4 y 4.5 (2022)– AEMPS, CIMA, nº registro 61426, revisión 07/2022, secciones 4.2, 4.4 y 4.5
- FDA: Metformin hydrochloride tablets (metformin) prescribing information (2026)– FDA, DailyMed, setid c82a10fa-1e8e-46b6-890a-737de3f34ee1 (Zydus), SPL 07/2026, sections 5.1, 7 and 12.3
- FDA: Tamsulosin hydrochloride capsules, Synthon (tamsulosin) prescribing information (2026)– FDA, DailyMed, Synthon B.V., setid 13a5032d-0be1-4001-916e-459f0b1a051d, v9, 10/2026, sections 4, 5.1, 5.2, 7 and 12.3